Synthesis and SAR of thiazolylmethylphenyl glucoside as novel C -aryl glucoside SGLT2 inhibitors

ACS Medicinal Chemistry Letters

Volumn 2, Issue 2, 2011, Pages 182-187

  Song, Kwang Seop ^a   Lee, Suk Ho ^a   Kim, Min Ju ^a   Seo, Hee Jeong ^a   Lee, Junwon ^a   Lee, Sung Han ^a   Jung, Myung Eun ^a   Son, Eun Jung ^a   Lee, Minwoo ^a   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

Author keywords

diabetes; glucoside; SAR; SGLT2; Thiazole

Indexed keywords

ANTIDIABETIC AGENT; BENZENE DERIVATIVE; DAPAGLIFLOZIN; GLUCOSE; GLUCOSIDE; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; THIAZOLE DERIVATIVE; THIAZOLYLMETHYLPHENYL GLUCOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION; URINARY EXCRETION; URINE VOLUME;

EID: 79951523123     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100256c     Document Type: Article

References (22)

1. International Diabetes Federation. Diabetes Atlas, 4 th ed.; International Diabetes Federation: Montreal, Canada, 2009.
2. Dwarakanathan, A. Diabetes update J. Insur. Med. 2006, 38, 20-30
3. Mackenzie, B.; Loo, D. D.; Panayotova-Heiermann, M.; Wright, E. M. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2 J. Biol. Chem. 1996, 271, 32678-32683 (Pubitemid 27008690)
4. Moe, O. W.; Berry, C. A.; Rector, F. C. The Kidney, 5 th ed.; Brenner, B. M.; Rector, F. C., Eds.; WB Saunders Co.: Philadelphia, PA, 2000; pp 375 - 415.
5. Washburn, W. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin. Ther. Patents 2009, 25, 1485-1499
6. Ellsworth, B. A.; Meng, W.; Patel, M.; Girotra, R. N.; Wu, G; Sher, P.; Hagan, D.; Obermeier, M.; Humphreys, W. G.; Robertson, J. G.; Wang, A.; Han, S.; Waldron, T.; Morgan, N. N.; Whaley, J. M.; Washburn, W. N. Aglycone exploration of C -arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2 Bioorg. Med. Chem. Lett. 2008, 18, 4770-4773
7. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, A. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2008, 51, 1145-1149 (Pubitemid 351480378)
8. Washburn, W. N. Development of the renal glucose reabsorption inhibitors: A new mechanism for the pharmacotherapy of diabetes mellitus type 2 J. Med. Chem. 2009, 52, 1785-1794
9. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanshi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel C -glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J. Med. Chem. 2010, 53, 6355-6360
10. Boehringer Ingelheim Pharmaceuticals, www.clinicaltrials.gov, 2010; NCT01164501.
11. Lexicon Pharmaceuticals, www.clinicaltrials.gov, 2009; NCT00962065. 12.
12. Astellas Pharma Inc., www.clinicaltrials.gov, 2010; NCT01135433.
13. Mascitti, V. Presented at the 240th American Chemical Society National Meeting and Exposition, Boston, MA, Aug 22-26, 2010; Medi-151.
14. Lee, J.; Lee, S.-H.; Seo, H. J.; Son, E.-J.; Lee, S. H.; Jung, M. E.; Lee, M.; Han, H.-K.; Kim, J.; Kang, J.; Lee, J. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-thiadiazolylmethylphenyl glucoside congeners Bioorg. Med. Chem. 2010, 18, 2178-2194
15. Kim, M. J.; Lee, J.; Kang, S. Y.; Lee, S.-H.; Son, E.-J.; Jung, M. E.; Lee, S. H.; Song, K.-S.; Lee, M.; Han, H.-K.; Kim, J.; Lee, J. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: pyridazinylmethylphenyl glucoside congeners Bioorg. Med. Chem. Lett. 2010, 20, 3420-3425
16. Kang, S. Y.; Song, K.-S.; Lee, J.; Lee, S.-H.; Lee, J. Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors Bioorg. Med. Chem. 2010, 18, 6069-6079
17. Lee, J.; Kim, J. Y.; Choi, J.; Lee, S.-H.; Kim, J.; Lee, J. Pyrimidinylmethylphenyl glucoside as novel C- aryl glucoside SGLT2 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 7046-7049
18. For cloning and cell line construction for human SGLT2, The h SGLT2 sequence was cloned into pcDNA3.1(+) for mammalian expression and were stably transfected into chinese hamster ovary (CHO) cells.
19. 50 was determined by nonlinear regression analysis using GraphPad PRISM. (20, 21)
20. Han, S.; Hagan, D. L.; Taylor, J. R.; Xin, L.; Meng, W.; Biller, S. A.; Wetterau, J. R.; Washburn, W. N.; Whaley, J. M. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 2008, 57, 1723-1729
21. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J. Pharmacol. Exp. Ther. 2007, 320, 323-330 (Pubitemid 46025747)
22. Nomura, S.; Kawanishi, E.; Ueta, K. Novel Compounds Having Inhibitory Activity Against Sodium-Dependent Transporter. PCT Int. Appl. WO2005012326.